Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 2/3 1

Status

Recruiting 1Not yet recruiting 1Completed 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Conditions

Melanoma 70Neoplasms 47Carcinoma, Non-Small-Cell Lung 26Colorectal Neoplasms 20Neoplasm Metastasis 15Multiple Myeloma 14Thyroid Neoplasms 12Glioma 12Pancreatic Neoplasms 11Hematologic Neoplasms 10Thyroid Carcinoma, Anaplastic 9Brain Neoplasms 8Lung Neoplasms 7Triple Negative Breast Neoplasms 5Rectal Neoplasms 5Neurofibromatosis 1 5Lymphoma 5Leukemia, Myeloid, Acute 5Colonic Neoplasms 5Breast Neoplasms 5Astrocytoma 5Thyroid Cancer, Papillary 4Prostatic Neoplasms 4Neurofibroma, Plexiform 4Glioblastoma 4Cholangiocarcinoma 4Biliary Tract Neoplasms 4Uveal Melanoma 3Skin Neoplasms 3Recurrence 3

Interventions

dabrafenib 4trametinib 3Tetracycline 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Interventional × Ameloblastoma × trametinib × Clear all
NCT06819605 2025-02-11

NETCAM-RCT

Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University

Phase 2/3 Not yet recruiting
46 enrolled

Ameloblastoma

NCT06653517 2024-10-22

NETCAM

Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University

Phase 2 Recruiting
12 enrolled

Ameloblastoma

NCT02367859 2024-01-30

Dabrafenib and Trametinib in Treating Patients With BRAF Mutated Ameloblastoma

Stanford University

Phase 2 Completed
1 enrolled 5 charts

Ameloblastoma, Adamantinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡